KDR and breast cancer: The monacolin X was treated along with VEGF to see the prevention of VEGF-induced proliferation of both MDA-MB231 and T47D cells and to check VEGFR2 downstream proteins in the phosphorylated form (pVEGFR2, pAkt1, pMAPKAPK2 and pERK1/2) and were quantified by immunofluorescence.67 This result strongly suggests that VEGF protects breast cancer cell viability via VEGFR2 (flk1/kdr) and monacolin X treatment is inhibiting the cell proliferation acting as VEGFR2.